Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ranok Closes $40 Million Series B for Protein Degredation Drugs

publication date: Aug 18, 2021

Ranok Therapeutics, a Hangzhou-Boston company, closed a $40 million Series B funding to advance its innovative targeted protein degradation technology. The company has developed a proprietary targeted protein degradation platform technology, CHAMP (Chaperone-mediated Protein Degradation). Chaperones are proteins that mark mis-folded proteins for degradation. The company plans to announce its lead program by the end of 2021. The B round was led by Lapam Capital and Shanghai Healthcare Capital, with Wu Capital, Zhongguancun Kaiyuan Capital also participating. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here